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Objective: We evaluated the treatment efﬁcacy of clomiphene citrate (CC) in hypogonadal men.
Methods: We retrospectively reviewed our patients with a diagnosis of hypogonadism who received CC
treatment, and compared the pretreatment and post-treatment serum testosterone levels. Subjective
patient improvements were recorded using the Androgen Deﬁciency in Aging Males questionnaire.
Results: A total of 10 patients were included in our analysis. Mean serum testosterone level increase from
246 ± 76 ng/dL to 548 ± 281 ng/dL was noted after treatment (p < 0.01). Eight (80%) patients successfully
reached a target serum testosterone level of > 400 ng/dL after treatment.
Conclusion: CC is an effective alternative treatment for patients with hypogonadism.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Male hypogonadism, referred to also as testosterone deﬁciency, is
amedical problemhighly prevalent in themiddle- and old-agedmale
populations. Approximately 20e30% of men in this population were
considered testosterone deﬁcient according to various studies, which
may be affected by aging and other comorbidities such as cardio-
vascular disease, diabetes, obesity, and metabolic syndrome.1,2 Ben-
eﬁts of testosterone replacement therapy are clearly established for
sexual function, increase in lean muscle mass and strength, mood
and cognitive function, and a possible reduction in frailty and oste-
oporosis.3 However, exogenous testosterone replacement causes
suppression of the hypothalamicepituitaryegonadal axis via a
negative feedback mechanism, which may lead to diminished
testicular size and consistency, and ultimately, infertility.4 This could
be a great concern in hypogonadal men who require exogenous
testosterone replacement but also wish to remain fertile.
Clomiphene citrate (CC) is a selective estrogen receptor modu-
lator that increases gonadotropin levels and consequently stimu-
lates testosterone and sperm production. CC may be used as an
alternative treatment for patients with hypogonadism when
maintenance of fertility is desired; however, limited publications
have demonstrated its treatment efﬁcacy,5 especially in the Asian, Nanya South Road, Banciao
ociation. Published by Elsevier Ta
et al., Clomiphene citrate tre
), http://dx.doi.org/10.1016/j.population. In this study, we investigated the efﬁcacy of CC in the
treatment of hypogonadism, with the objectives of assessing the
increase in endogenous serum testosterone and evaluating the
patients' subjective improvement of symptoms.
2. Materials and methods
We retrospectively reviewed the patients diagnosed with
hypogonadism who received CC in our center in 2015. Hypo-
gonadism is deﬁned as a low serum testosterone (< 300 ng/dL) and
requires the patient presenting with symptoms of hypogonadism.
For patients who wish to receive testosterone replacement but also
desire fertility, CC is offered as an alternative treatment. However,
due to lack of safety information on CC use in patients contra-
indicated to testosterone replacement therapy, patients with con-
cerns of pre-existing prostate cancer, signiﬁcant erythrocytosis,
untreated obstructive sleep apnea, and untreated severe congestive
heart failure were excluded from receiving CC treatment. CC was
offered at the patient's discretion after having extensive discussion
with the treating urologist regarding the available treatment op-
tions and their risks. For those who decided to receive CC treat-
ment, each patient was treated with a daily dose of 50 mg CC. The
patients were evaluated after at least 3 weeks of CC administration
for serum testosterone levels. The Androgen Deﬁciency in Aging
Males questionnaire was administered before treatment and dur-
ing follow up for subjective outcome measures. The patients were
monitored for side effects, in a similar manner to patients receiving
testosterone replacement therapy, and were recorded respectively.iwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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90 days before CC was initiated were excluded from our analysis.
Statistical analysis was performed using SPSS (IBM SPSS Statis-
tics Version 20), with p values < 0.05 considered statistically sig-
niﬁcant. Mean and standard deviation of the studied variables were
reported. Wilcoxon signed-rank test was used to compare the
pretreatment and post-treatment serum testosterone level and
other variables. We used ManneWhitney U test to compare the
mean serum testosterone change between different patient groups
in our subgroup analysis.
Our study obtained ethical approval from our local institutional
review board.Figure 1. Pretreatment and post-treatment serum testosterone level (ng/dL) after
daily 50 mg clomiphene citrate (values expressed as mean and standard deviation).3. Results
A total of 15 patients with hypogonadism were treated with CC
in our center in 2015. The post-treatment serum testosterone level
was not available in ﬁve patients, who were excluded from our
analysis. Ten patients completed post-treatment evaluation and
were included for analysis. The mean age of our patients was
50.5 ± 12.5 years. Our patients were generally healthy without
signiﬁcantmedical comorbidities, with the exception of one patient
with underlying hypertension and diabetes mellitus, and another
patient with hyperlipidemia. All patients had at least one symptom
suggestive of hypogonadism. Erectile dysfunction was the most
presented symptom, which was seen in all 10 (100%) patients.
Other hypogonadal symptoms included decreased libido in eight
(80%) patients, general malaise in ﬁve (50%) patients, and infertility
in two (20%) patients (Table 1).
Mean pretreatment serum testosterone level was 246 ± 76 ng/
dL. After a treatment interval ranging from 20 days to 193 days, the
mean post-treatment serum testosterone level increased to
548 ± 281ng/dL, which was statistically signiﬁcant (p <0.01;
Figure 1). The number of successfully treated patients with target
serum testosterone level reaching  400 ng/dL was eight patients
(80%). Within 35 days, six (60%) patients had reached the target
serum testosterone level. Of the two men whose treatment failed,
one 64-year-old patient had an initial testosterone level of 60 ng/
dL, which was profoundly low compared with the average of pa-
tients in our study, with no change noted after CC treatment for
2 months. Serum testosterone level improvement from 248 ng/dL
to 336 ng/dL was noted in the other 50-year-old patient, although
this did not reach the treatment target level.
Patient subjective treatment response was evaluated using the
Androgen Deﬁciency in Aging Males questionnaire. The meanTable 1
Patient characteristics and treatment results after clomiphene citrate.
No. of patients 10
Age (y) 50.5 ± 12.5
Presenting symptoms
Erectile dysfunction 10 (100)
Low libido 8 (80)
General malaise 5 (50)
Depressive moods 5 (50)
Infertility 2 (20)
Medical comorbidities
Hypertension 1 (10)
Diabetes mellitus 1 (10)
Hyperlipidemia 1 (10)
Pretreatment serum T 246 ± 76
Post-treatment serum T 548 ± 281
Successfully treated patientsa 8 (80)
Data are presented as n (%) or mean ± SD.
SD ¼ standard deviation; T ¼ testosterone.
a Deﬁned as post-treatment serum T > 400 ng/dL.
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was 5.9 ± 1.9 before CC treatment, and improved to 1.7 ± 1.1 after
treatment, whichwas, however, statistically insigniﬁcant (p¼ 0.10).
There were no side effects reported during the entire treatment
course.
We performed a subgroup analysis of our patients, where the
patients aged  50 years were compared with the patients aged <
50 years for treatment efﬁcacy of CC. The mean serum testosterone
change after CC treatment was 198 ± 174 ng/dL in the older patient
group, compared with 455 ± 255 ng/dL in the younger patient
group, which was statistically insigniﬁcant (p ¼ 0.08; not included
in Table 1).4. Discussion
Hypogonadism consists of a variety of nonspeciﬁc symptoms
including decreased libido, fatigue, poor concentration, erectile
dysfunction, lack of concentration and depressed mood, which
could often be unnoticed by patients or treating physician, making
the diagnosis particularly difﬁcult.6 This underdiagnosed and
undertreated medical condition is associated with obesity, insulin
resistance, and an adverse lipid proﬁle in men, and is indepen-
dently associated with increased all-cause and cardiovascular
mortality.7 The prevalence of hypogonadism is related to aging.8
Because the Taiwanese population represents an aging society
with continued increase of life expectancy, the impact of this
medical condition will be increasingly important. Testosterone
replacement is the current mainstay treatment, with well-
established beneﬁts to the quality of life of men in middle and
old age, especially in terms of body composition, muscle, and bone.1
Despite higher prevalence in the elderly population, hypo-
gonadism may also affect younger patients. For these younger pa-
tients of reproductive age, testosterone replacement therapy may
greatly compromise their fertility because of downregulation of
gonadotropins causing diminished testicular size and function.4
Although this subinfertility condition is often reversible after
cessation of exogenous testosterone supplement, it is still worri-
some for those patients who remain interested in fertility.9,10 CC
has been studied as an alternative treatment.
CC is a selective estrogen receptor modulator that could indi-
rectly increase serum testosterone by competing with estradiol ateatment outcomes in Taiwanese hypogonadal men: A single-center
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tive feedback for gonadotropin release. While CC is not Food and
Drug Administration approved for hypogonadism, it has been used
off label for many years.10,11 Although only a limited number of
relevant publications without a strong level of evidence exist, most
have shown efﬁcacious treatment of CC in hypogonadal men. In a
cohort of 86 young patients with mean age 29 years, Katz et al10
showed signiﬁcant improvement in serum testosterone level and
subjective responses after CC. Taylor and Levine12 compared pa-
tients receiving CC (65 patients) and testosterone gel replacement
therapy (39 patients) and demonstrated equal efﬁcacy, with lower
cost in the CC group. However, their average patient age was
42 years (CC) versus 57 years (testosterone gel). Ramasamy et al11
compared 93 hypogonadal men on testosterone injections or gels
or CC, and found that the post-treatment median serum total
testosterone level in men on CC was lower than in men receiving
testosterone injections but similar to that in men on testosterone
gels. The median age in all groups was 40e44 years. Moskovic
et al13 followed up 46 patients for 3 years and demonstrated the
long-term safety and efﬁcacy of CC. Although promising results of
CC treatment in hypogonadal men were shown in the aforemen-
tioned studies, these studies did not demonstrate the use of CC in
more elderly populations.
In a previous study including older patients, Tenover et al14
compared 1 week of CC therapy in younger (22e35 years) and
older (65e84 years) patients, and reported that the elderly group
had signiﬁcantly lower serum total testosterone and non-SHBG-
bound (bioavailable) testosterone levels than did younger men.
However, due to the small patient number (29 patients and 26
patients in each group) and the more extreme age in the older
patient group (> 65 years), the efﬁcacy of CC in the older population
remains inconclusive.
In our study, eight (80%) patients reached the target serum
testosterone level of > 400 ng/dL after CC treatment, with a mean
serum testosterone level increase from 246 ± 76 ng/dL to
548 ± 281 ng/dL. We have shown treatment results (including
safety and efﬁcacy) comparable with the earlier studies, however,
our mean patient age was 50.5 years, showing the efﬁcacy of CC in
the older cohort of patients. Furthermore, to our knowledge, this is
the ﬁrst study describing the treatment results of CC in Asian
hypogonadal men. We have demonstrated the rapid treatment ef-
fect of CC, with most patients (60%) in our study cohort reaching
target serum testosterone level within 35 days, whereas the
remaining patients did not demonstrate this rapid treatment effect
due to different follow-up protocols for serum testosterone. The
average expense of drug treatment for patients who received CC in
this study was NTD180/mo, which is much lower than for patients
receiving exogenous testosterone replacement therapy. Due to the
overall beneﬁt of high efﬁcacy, low adverse events, and low cost, CC
could even be suggested as an initial treatment for hypogonadal
patients.
Our limitations include the small patient cohort of our study,
and its single-armed and retrospective nature. Clinical information
such as body mass index or waist circumference were not available
in our study; therefore we could not demonstrate the inﬂuence of
obesity on our treatment results. Furthermore, some importantPlease cite this article in press as: Tan J-S, et al., Clomiphene citrate tre
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hematocrit levels before and after CC treatment, were not included
in our analysis due to the retrospective nature of this study. Pre-
treatment testicular volumes and luteinizing hormone levels have
been shown in a previous study as factors predictive of CC treat-
ment response in hypogonadal men,15 where patients with low
pretreatment testicular volumes and high luteinizing hormone
levels had a lower success rate from CC treatment, which suggests
that patients with primary testicular failure could not beneﬁt well
from CC treatment. However, we did not routinely screen our pa-
tients for primary testicular failure features before initiating CC
treatment, therefore this study was unable to demonstrate the
different treatment results in patients with different primary cau-
ses of hypogonadism.
5. Conclusion
In conclusion, CC is a safe and effective alternative treatment for
hypogonadal men, which has a role for those unable to receive
testosterone replacement therapy due to concerns of infertility.
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